secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0001787306-25-000142
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis Q3 2025 net product revenue $99.2M (+122% YoY); turns profitable; FY2026 guidance $455-470M
--------------------------------------------------------------------------------

- Net product revenue $99.2M (+122% YoY, +22% sequential); driven by ZORYVE cream and foam.
- Net income $7.4M ($0.06 EPS) vs net loss $41.5M ($0.33 loss per share) in Q3 2024.
- FDA approved ZORYVE cream 0.05% for atopic dermatitis in children 2-5; launch by end of October.
- Initial FY2026 net product revenue guidance of $455-$470M; peak ZORYVE sales target $2.6-3.5B.
- Phase 2 trials started for ZORYVE foam 0.3% in vitiligo and hidradenitis suppurativa.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730625000142/0001787306-25-000142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730625000142/arqt-20251028.htm
  HTML page:      https://secwatch.observer/filing/0001787306-25-000142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer